SUMMARY
Metastatic breast cancer is considered incurable, with a 5-year survival of approximately 23%. However, sequential chemotherapy regimens produce clinical benefit for patients, including prolonged progression-free and overall survival times. Eribulin is a convenient (<5 min infusion) and novel treatment that has shown activity and efficacy and tolerability in advanced breast cancer patients in Phase II and Phase III trials. Eribulin has also shown encouraging results as first-line treatment, either alone in patients with HER2- disease or in combination with trastuzumab in patients with HER2+ disease, in Phase II trials.
Financial & competing interests disclosure
LS Schwartzberg is a consultant/advisor for and has received funding from Eisai Inc. and Helsinn. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Writing and editorial support was provided by Leonard Lionnet, PhD, of MedVal Scientific Information Services. This manuscript was prepared according to the International Society for Medical Publication Professionals’ “Good Publication Practice for Communicating Company-Sponsored Medical Research: The GPP2 Guidelines.” Funding to support the preparation of this manuscript was provided by Eisai Inc.